TickerFacts.

Telomir Pharmaceuticals, Inc. (TELO): Shareholders' Equity

Annual figures by period end, from SEC filings.

$5.91M
As of 2025-12-31
$5.03M
As of 2026-06-30
2022-12-31: -$937.3K2023-12-31: $3.44M2024-12-31: $643.0K2025-12-31: $5.91M$5.91M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$5.91M+819.6%2026-03-17, Balance as of period end
2024-12-31$643.0K-81.3%2026-03-17, Balance as of period end
2023-12-31$3.44Mn/m2025-02-04, Balance as of period end
2022-12-31-$937.3Kn/a2024-03-29, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Telomir Pharmaceuticals, Inc. (TELO)2025-12-31$5.91M+819.6%
Ensysce Biosciences, Inc. (ENSC)2025-12-31$3.21M-13.3%
Matinas BioPharma Holdings, Inc. (MTNB)2025-12-31$4.83M-36.4%
Oncolytics Biotech Inc (ONCY)2025-12-31-$3.80Mn/m
Rocket One Inc. (RKTO)2025-12-31$6.15M-10.6%
Silo Pharma, Inc. (SILO)2025-12-31$6.31M+25.3%
Cannapharmarx, Inc. (CPMD)2025-12-31-$30.15Mn/m
Acurx Pharmaceuticals, Inc. (ACXP)2025-12-31$5.27M+756.5%
CV Sciences, Inc. (CVSI)2025-12-31$1.47M-18.2%

Compare TELO, ENSC, MTNB, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗